Welcome to AIDS PATIENT CARE AND STDS, a leading journal dedicated to the comprehensive exploration of clinical practices, research advancements, and public health strategies centered around HIV/AIDS and sexually transmitted diseases. Published by Mary Ann Liebert, Inc., this esteemed journal has been at the forefront of disseminating critical findings since 1996, contributing to a robust understanding of the complexities surrounding these global health issues. With an impressive impact factor reflected in its 2023 Q1 quartile rankings in both Infectious Diseases and Public Health, Environmental and Occupational Health, the journal stands out among its peers, ranking at the 95th percentile for Public Health and 91st percentile in Infectious Diseases. Researchers, healthcare professionals, and students will benefit from its rich content, comprehensive studies, and critical reviews that aim to improve care practices and health outcomes. With a clear commitment to fostering knowledge and collaboration in the field, AIDS PATIENT CARE AND STDS is an essential resource for those dedicated to combating these pressing health challenges.

AIDS RESEARCH AND HUMAN RETROVIRUSES, published by Mary Ann Liebert, Inc., is a pivotal journal dedicated to advancing the field of HIV research and the broader spectrum of human retroviruses. With an ISSN of 0889-2229 and an E-ISSN of 1931-8405, this journal has been in continuous publication since 1987 and is respected in the academic community for its rigorous peer-reviewed articles. As a Q3 ranked journal in Immunology, Infectious Diseases, and Virology as of 2023, it plays a crucial role in disseminating cutting-edge research, theoretical advancements, and clinical insights that contribute significantly to the understanding and treatment of HIV and related disorders. The journal's objective is to foster collaboration among researchers, healthcare professionals, and educators by providing a platform for the exchange of innovative ideas and findings. Although not an open-access journal, its compelling content ensures that it remains a primary resource for those in the academic and medical communities tackling the challenges posed by retroviral infections. With a commitment to excellence and relevance, AIDS RESEARCH AND HUMAN RETROVIRUSES continues to shape the future of research in this critical area.

INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.

VIROLOGICA SINICA, published by KEAI PUBLISHING LTD, is a leading international journal dedicated to the field of virology. With an ISSN of 1674-0769 and E-ISSN of 1995-820X, this esteemed journal showcases cutting-edge research from 2006 to 2024, focusing on critical developments in Immunology, Infectious Diseases, Molecular Medicine, and Virology. As evidenced by its respectable positioning in the Q2 quartile of relevant categories and impressive Scopus rankings—such as Rank #20/80 in Virology—VIROLOGICA SINICA serves as an essential resource for researchers, professionals, and students aiming to deepen their understanding of viral pathogens and their impact on human health. While the journal does not currently offer open access, it remains an invaluable publication for those seeking to stay at the forefront of virology research. Its address is located at 16 Donghuangchenggen North St, Beijing, China, where it continues to foster academic excellence in the rapidly evolving landscape of virology.

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA is a prominent journal dedicated to the fields of infectious diseases and clinical microbiology, published by EDICIONES DOYMA S A in Spain. With an ISSN of 0213-005X and an e-ISSN of 1578-1852, the journal has been a cornerstone of research and scholarly communication since its inception in 1989. As of 2023, it holds a Q3 category ranking in Infectious Diseases, highlighting its significance in the field, alongside a Q4 ranking in the related area of Microbiology. Although the journal is not open access, it remains an essential resource for professionals, researchers, and students aiming to stay informed on advancements and studies that impact clinical practices in infectious diseases. With Scopus ranks indicating a percentile ranking in the 20th to 34th range across various sub-disciplines, ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA continually contributes to the dialogue and development of science, fostering a deeper understanding of complex microbial interactions and disease mechanisms.

SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, published by AOSIS, stands as a vital resource in the field of Infectious Diseases, particularly focusing on HIV medicine. With an ISSN of 1608-9693 and E-ISSN 2078-6751, this Open Access journal has been dedicated to disseminating cutting-edge research since 2001, ensuring that findings are accessible to a global audience of researchers, healthcare professionals, and students. Operating out of South Africa, the journal has earned a position in the Q3 quartile for Infectious Diseases, reflecting its commitment to advancing the understanding and treatment of HIV-related issues. Its Scopus ranking, presently at #207 out of 344, further emphasizes its scholarly influence, positioning it as an essential publication within the medical community. The journal aims to foster collaboration and innovation in HIV research and practice, bridging gaps between theory and real-world application to improve health outcomes in southern Africa and beyond.

Journal of the International Association of Providers of AIDS Care, published by SAGE PUBLICATIONS INC, is a distinguished open-access journal dedicated to the field of HIV/AIDS care and research. Since its inception in 2002, the journal has provided an essential platform for the dissemination of high-quality, peer-reviewed scholarly articles that advance knowledge in exciting areas such as dermatology, immunology, and infectious diseases. With an impact factor that highlights its role in shaping ongoing discourse, the journal boasts a strong reputation, reflected in its Q1 status in Dermatology and consistent ranking in the top tiers for immunology and infectious diseases in the Scopus Ranks. This commitment to excellence ensures that researchers, healthcare professionals, and students have access to the latest advancements and best practices in HIV/AIDS prevention and care. As a pivotal resource in the global health landscape, the journal stands at the forefront of efforts to combat the challenges presented by this ongoing epidemic.

The Lancet HIV, published by Elsevier Inc in the United Kingdom, stands at the forefront of HIV research and public health, providing a vital platform for the dissemination of innovative findings and critical knowledge in the fields of epidemiology, immunology, infectious diseases, and virology. With its prestigious Q1 rankings in the aforementioned categories for 2023, the journal is recognized for its significant contribution to advancing understanding and addressing challenges posed by HIV globally. Its impressive standing, including a Scopus ranking in the 94th percentile for multiple categories, underscores its impact within the research community. The Lancet HIV publishes rigorously peer-reviewed research articles, reviews, and opinion pieces, ensuring that all stakeholders—researchers, practitioners, and policymakers—are engaged with up-to-date, evidence-based perspectives. Researchers and students alike will find this journal an invaluable resource for enhancing their knowledge and contributing to the ongoing discourse surrounding HIV treatment and prevention.

MICROBIAL PATHOGENESIS, published by Academic Press Ltd - Elsevier Science Ltd, is a prominent journal in the fields of Infectious Diseases and Microbiology, with a notable impact factor and classified in the Q2 quartile for both categories as of 2023. Since its inception in 1986, this journal has provided a platform for the dissemination of cutting-edge research that enhances our understanding of microbial infections and their implications in health and disease. The journal is indexed in Scopus, ranking #80 among 344 in Infectious Diseases and #57 among 182 in Microbiology, underscoring its significant contribution to the scientific community. Although it operates under a traditional subscription model, the content is vital for researchers, professionals, and students focused on the dynamics of microbial pathogenesis and the development of innovative therapeutic strategies. The journal's comprehensive scope aims to foster advancements in this critical area of study, bridging the gap between laboratory research and clinical applications.